Chaga
Chaga (Inonotus obliquus) is a polypore fungus that grows as a black, cracked sterile conk on the trunks of birch trees in cold-temperate forests across Russia, Northern Europe, and North America. Used traditionally as a tea, increasingly available in UK supplements as fruit-body extract. The published human evidence is very limited; EFSA has not authorised any UK health claim. Two specific safety cautions apply: oxalate kidney-stone risk and theoretical bleeding risk.
Camden Medicals editorial · Last reviewed 27 April 2026 · Next review April 2027
- Cross-checked against
- NHS
- NICE
- BNF
- EFSA
- FSA
Camden's editorial team independently graded each health claim below on the strength of the published evidence — see the grade beside every condition.
- Class
- Mushroom
- Typical daily dose
- No UK consensus. Commercial UK supplements typically deliver 500-2,000 mg of mushroom equivalent per serving.
- Top use evidence
- Insufficient
On this page
What it is
Chaga is the sterile mycelial conk of Inonotus obliquus, a polypore fungus parasitic on birch trees (Betula species). Unlike most edible mushrooms — which are the fruiting body of the fungus — what consumers harvest from a birch trunk is a mass of fungal mycelium embedded with tree-bark fragments, melanin pigments, and oxalates. The black, hard, charcoal-like external appearance reflects melanin content; the orange-brown interior is the fungal mass.
Traditional use is as a tea or decoction, particularly in Siberian and Eastern European folk medicine. Modern UK supplements supply it as fruit-body / sclerotium extract powder, capsules, or tinctures.
Two compound classes are usually invoked in marketing: melanin and polyphenolic compounds (claimed antioxidant) and beta-glucan polysaccharides (claimed immune effects). Most of the underlying research is in cell or animal models; large or methodologically- strong human trials are essentially absent.
At a glance
- Polypore fungus parasitic on birch; traditionally consumed as a tea in Russia and Eastern Europe.
- No GB-authorised health claim. EFSA evaluation of botanical health claims has been on hold since 2010.
- Almost no published human RCT evidence — most claims rest on cell-culture or animal studies, which do not translate reliably.
- Two specific safety concerns: high oxalate content (kidney-stone risk; documented case reports of acute oxalate nephropathy) and possible bleeding risk (animal data on platelet aggregation).
- Caution in chronic kidney disease, kidney-stone history, anticoagulant users, and pregnancy. Talk to your pharmacist before use if you take diabetes medication — animal data suggest blood-sugar lowering effects.
What people use it for
People exploring traditional botanicals for general well-being
Traditional-use history in Siberian and Eastern European folk medicine. The traditional-use frame is permissible in UK marketing; specific health claims are not authorised. Pharmacological RCT evidence in healthy adults is essentially absent.
Popular, not provenInsufficientPeople exploring antioxidant supplements
Chaga is high in polyphenolic compounds and melanin. Whether dietary supplementation translates to clinically-meaningful antioxidant outcomes in humans is not established by trial evidence; this remains an animal-and-cell-model story.
Popular, not provenInsufficient
How it works
In cell-culture and animal models, chaga extracts have shown antioxidant, anti-inflammatory, and immune-modulating effects. The melanin and polyphenolic content is high. None of these mechanistic findings has been demonstrated to translate into clinically-meaningful outcomes in human RCTs.
Common myths
Myth"Chaga has the highest ORAC (antioxidant) score of any food"
RealityORAC values are an in-vitro test that has been disowned by the US Department of Agriculture (which removed its ORAC database in 2012) because the values do not predict in-vivo antioxidant effects in humans. Any food with high pigment content scores high; the score has no clinical meaning.
Myth"Chaga prevents or treats cancer"
RealityIt does not. There is essentially no human clinical evidence to support cancer-related claims. Marketing chaga for a cancer indication crosses into MHRA medicines-borderline territory and is not appropriate. Cell-culture studies do not translate.
Myth"Chaga is safe because it is "just a mushroom tea""
RealityChaga has caused documented case reports of acute oxalate nephropathy (oxalate-driven acute kidney injury), particularly in people taking high doses for months and in those with existing kidney disease. Three PubMed-indexed human case reports describe acute kidney injury after chronic chaga use (Kikuchi 2014, Lee 2020, Kwon 2022). The oxalate content is high and not removed by standard preparation methods. [3,2,4]
Common online questions
Synthesised from the questions UK shoppers most often ask online about Chaga. Each answer is editorial and links to its evidence in the Sources list below.
Is chaga safe for everyone?
No. Three groups should avoid or only use under clinician supervision: people with kidney disease or a history of kidney stones (acute oxalate nephropathy is a documented case report); people taking anticoagulants (animal data on platelet effects); and people on diabetes medication (chaga has shown blood-sugar lowering in animal models — concurrent insulin or sulfonylurea could potentiate hypoglycaemia). Pregnancy and breastfeeding: insufficient data — avoid.
Will chaga prevent or cure cancer?
No. Marketing chaga for cancer prevention or treatment is not supported by human evidence and crosses into MHRA medicines- borderline territory. Cell-culture and animal data do not translate to clinical outcomes. If you are interested in adjunctive therapies during cancer treatment, talk to your oncology team — do not self-add chaga.
Is chaga an antioxidant?
It contains polyphenols and melanin in vitro. Whether oral chaga supplementation produces clinically meaningful antioxidant outcomes in healthy humans is not established by trial evidence. The "ORAC superfood" framing rests on a lab test the US Department of Agriculture withdrew in 2012 because it did not predict in-vivo effects.
I have diabetes — can I take chaga?
Talk to your GP first. Animal models suggest chaga has blood-sugar lowering effects, which could potentiate insulin or sulfonylurea therapy — that is the diabetes-specific signal. Diabetes also raises baseline kidney-injury risk regardless of supplement use, and chaga has documented kidney-injury case reports in chronic high-dose use, so combining the two argues for clinician oversight rather than self-supplementation.
Fruit body vs tea — which is the traditional form?
The traditional Russian and Siberian use is a long-decoction tea — the conk is dried, broken, and simmered for hours. Modern UK supplements supply concentrated extract powders. Concentration of bioactive compounds is higher in extracts; so is the per-mass oxalate content. The tea route delivers a smaller dose.
🔬 Camden’s evidence review
The research Camden reviewed, graded on its strength. This is our own appraisal — it sits beneath the official guidance above, never above it.
All human clinical outcomes
InsufficientEvidenceinsufficientDespite extensive cell-culture and animal-model literature, published human RCT evidence on chaga is essentially absent. Marketing claims about cancer, immune function, or cardiovascular outcomes substantially outrun the human evidence base.
Safety
Chaga is NOT a benign mushroom tea — three published human case reports document acute oxalate kidney injury after chronic high-dose use, particularly in people with existing kidney issues. EFSA has not authorised any UK health claim. Talk to a clinician before using if any of the scenarios below apply, and report any suspected adverse reaction to the MHRA via the Yellow Card scheme.
Talk to your pharmacist or GP first if you:
- You have chronic kidney disease or any kidney concern.
- You have a history of kidney stones (especially calcium-oxalate stones).
- You take diabetes medication (animal data suggest blood-sugar lowering effects — risk of hypoglycaemia with insulin or sulfonylurea).
- You take an anticoagulant (animal data on platelet effects).
- You are pregnant, breastfeeding, or thinking of becoming pregnant.
- You have a known mushroom allergy.
- You take immunosuppressants.
Common side effects: Mild digestive complaints in the first few days. Rare allergic reactions. Acute oxalate nephropathy with chronic high-dose use (rare but documented).
Pregnancy and breastfeeding
Insufficient safety data; oxalate concentration argues for avoidance in pregnancy. Talk to your midwife or GP.
Same framing.
Talk to your GP, midwife, or pharmacist before starting any supplement during pregnancy or breastfeeding.
More clinical detail (for clinicians and informed readers)
Contraindications
- Chronic kidney disease (any stage).
- History of calcium-oxalate kidney stones.
- Known mushroom allergy.
Drug interactions
- Anticoagulants — animal data on platelet effects; clinical interaction data limited.
- Insulin and other diabetes medication — chaga has shown blood-sugar lowering effects in animal models. Concurrent use could potentiate hypoglycaemia. Discuss with your prescriber before adding chaga to a diabetes regimen.
- Immunosuppressants — theoretical immune-modulation.
This is not an exhaustive list. Always tell your prescriber and pharmacist about every supplement you take.
Common side effects
- Mild digestive complaints reported occasionally.
Rare side effects
- Acute oxalate nephropathy (acute kidney injury from oxalate crystal deposition). Three PubMed-indexed human case reports as of 2026 (PMIDs 23149251, 32419395, 35451393), all involving chronic high-dose chaga use over months.
- Allergic reactions in mushroom-allergic individuals.
How to take it
- Typical supplemental range
- No UK consensus. Commercial UK supplements typically deliver 500-2,000 mg of mushroom equivalent per serving.
- Timing
- No specific timing requirement.
How to spot quality
Look for
- Substrate / source: wild-harvested vs cultivated; fruit body vs sclerotium.
- Beta-glucan percentage stated specifically.
- GMP-certified manufacture; ideally third-party heavy-metals testing (chaga can concentrate environmental metals from birch substrate).
- Country of origin disclosed.
Red flags
- Cancer-treatment claims or "ORAC superfood" marketing claims.
- "Immune-boost" claims that go beyond authorised UK wording.
- No oxalate-content disclosure.
Commonly combined with
Other ingredients that share a biological pathway, cofactor relationship, or evidence-backed protocol with this one. Mechanisms below cite primary physiology — not folk pairing. Doses are literature ranges, not recommendations. Talk to your pharmacist or GP before changing your stack, especially if you take prescription medication.
Reishi
Limited evidenceMycofera mushroom-cluster siblings — both contain β-(1-3,1-6) glucan + species-specific polyphenols (chaga melanin, reishi triterpenoids).
Chaga delivers β-glucan + melanin polysaccharide-protein complexes; reishi delivers β-glucan + ganoderic-acid triterpenoids. Mechanism complementary.
Evidence: Camden NB-502 bundles both.
Doses studied: 300-1000 mg chaga + 300-500 mg reishi extracts daily.
Found in Camden: Mycofera™ Mushroom Complex 120 Capsules
Beta-Glucan (β-glucan)
Limited evidenceChaga β-(1-3,1-6) glucan + melanin polysaccharide complexes — Camden beta-glucan is the cluster molecular pillar.
Chaga has higher melanin content than other medicinal mushrooms — may contribute additional antioxidant signalling beyond standard β-glucan Dectin-1 mechanism.
Evidence: Camden beta-glucan covers cluster.
Doses studied: 300-1000 mg chaga extract daily.
Found in Camden: Mycofera™ Mushroom Complex 120 Capsules
Cordyceps
Limited evidenceMycofera adaptogen-mushroom cluster — chaga + cordyceps appear together in many UK mushroom blends.
Chaga immune-modulation + cordyceps energy / cordycepin signalling. Mechanism complementary across innate immune + bioenergetic axes.
Evidence: Camden NB-502 bundles cordyceps.
Doses studied: 300-1000 mg each daily.
Found in Camden: Mycofera™ Mushroom Complex 120 Capsules